摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methylazetidin-3-ol trifluoroacetic acid salt | 1104083-24-0

中文名称
——
中文别名
——
英文名称
3-methylazetidin-3-ol trifluoroacetic acid salt
英文别名
3-methylazetidin-3-ol trifluoroacetate;3-methylazetidin-3-ol 2,2,2-trifluoroacetate;3-Methylazetidin-3-ol; trifluoroacetic acid;3-methylazetidin-3-ol;2,2,2-trifluoroacetic acid
3-methylazetidin-3-ol trifluoroacetic acid salt化学式
CAS
1104083-24-0
化学式
C2HF3O2*C4H9NO
mdl
MFCD27977183
分子量
201.146
InChiKey
ANQVEPVLABFZDZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.91
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.833
  • 拓扑面积:
    69.6
  • 氢给体数:
    3
  • 氢受体数:
    7

安全信息

  • 储存条件:
    室温

反应信息

  • 作为反应物:
    描述:
    3-methylazetidin-3-ol trifluoroacetic acid salt 、 (5S)-6-[4-fluoro-3-(trifluoromethyl)phenyl]-5-methyl-4,5-dihydro-1,2,4-triazin-3(2H)-one 在 N,N-二异丙基乙胺 作用下, 以 二甲基亚砜 为溶剂, 生成 (5S)-6-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-5-methyl-4,5- dihydro-1,2,4- triazin-3(2H)-one
    参考文献:
    名称:
    [EN] 1,2,4-TRIAZIN-3(2H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    [FR] COMPOSÉS DE 1,2,4-TRIAZIN-3(2H)-ONE POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES
    摘要:
    本发明包括通式(I)的命名化合物:(I)其中R1、R2、R3和R4如本文所定义,其制备方法,含有所述化合物的药物组合物和药物组合物的使用,用于治疗过度增殖性疾病。
    公开号:
    WO2020157194A1
  • 作为产物:
    描述:
    1-(二苯基甲基)-3-甲基-3-羟基氮杂啶三氟乙酸氢氧化钯 乙醚 作用下, 以 乙醇 为溶剂, 25.0 ℃ 、45.96 MPa 条件下, 反应 16.0h, 生成 3-methylazetidin-3-ol trifluoroacetic acid salt
    参考文献:
    名称:
    SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
    摘要:
    式(I)的化合物及其盐,其中R1、R2、R3、R4、X、Y和n的含义如规范中所述,是Trk激酶的抑制剂,可用于治疗可以用Trk激酶抑制剂治疗的疾病,例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
    公开号:
    US20120108568A1
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DES TRK KINASES
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2011006074A1
    公开(公告)日:2011-01-13
    Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    式(I)的化合物及其盐,其中R1、R2、R3、R4、X、Y和n的含义如规范中所述,是Trk激酶的抑制剂,并且在治疗可以用Trk激酶抑制剂治疗的疾病中具有用处,如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
  • [EN] 1,2,4-TRIAZIN-6(1H)-ONE COMPOUNDS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES<br/>[FR] COMPOSÉS DE 1,2,4-TRIAZIN-6(1H)-ONE POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES
    申请人:BAYER AG
    公开号:WO2020157189A1
    公开(公告)日:2020-08-06
    The present invention includes name compounds of general formula (I) in which R1, Y, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    本发明包括一般式(I)中的命名化合物,其中R1、Y、R3和R4如本文所定义,制备所述化合物的方法,用于制备所述化合物的中间化合物,包含所述化合物的药物组合物和组合物,以及使用所述化合物制造用于治疗或预防疾病的药物组合物,特别是治疗过度增殖性疾病的药物组合物,作为单一药剂或与其他活性成分组合使用。
  • Pyrrolopyrazine Kinase Inhibitors
    申请人:Hendricks Robert Than
    公开号:US20110230462A1
    公开(公告)日:2011-09-22
    The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables n, p, q, Q, X, X′ and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
    本发明涉及使用新型吡咯吡嗪衍生物的公式I,其中变量n、p、q、Q、X、X'和Y如本文所述定义,这些衍生物抑制JAK和SYK,并且适用于治疗自身免疫和炎症性疾病。
  • Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
    申请人:Allen Shelley
    公开号:US08791123B2
    公开(公告)日:2014-07-29
    Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    式(I)的化合物及其盐,其中R1、R2、R3、R4、X、Y和n的含义如说明书所述,是Trk激酶的抑制剂,可用于治疗可通过Trk激酶抑制剂治疗的疾病,如疼痛、癌症、炎症、神经退行性疾病和某些传染性疾病。
  • Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors
    申请人:Array BioPharma Inc.
    公开号:US20150031667A1
    公开(公告)日:2015-01-29
    Compounds of Formula I: and salts thereof in which R 1 , R 2 , R 3 , R 4 , X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    公式I的化合物及其盐,其中R1、R2、R3、R4、X、Y和n的含义如说明书所述,是Trk激酶的抑制剂,并可用于治疗可以用Trk激酶抑制剂治疗的疾病,如疼痛、癌症、炎症、神经退行性疾病和某些传染性疾病。
查看更多